A PET agent built around fluorine-18 readily and safely distinguished the brains of Alzheimer's disease patients from those of healthy volunteers in a clinical trial at Johns Hopkins University.
A PET agent built around fluorine-18 readily and safely distinguished the brains of Alzheimer's disease patients from those of healthy volunteers in a clinical trial at Johns Hopkins University.
Dr. Dean F. Wong, a professor of radiology and psychiatry at Johns Hopkins, and colleagues plugged F-18 into a compound known as florbetapir F-18, which is drawn to the beta-amyloid in Alzheimer's plaques. The compound has a half-life of about 110 minutes.
Testing the new compound in humans, Wong and his colleagues recruited 26 volunteers, 11 previously diagnosed with Alzheimer's disease and 15 healthy subjects of similar age who performed normally on cognitive tests. Each volunteer received a florbetapir PET scan, acquired over 90 minutes. The Alzheimer's patients showed significantly more of the agent in their brains than the healthy volunteers with the radiotracer accumulating in regions known to be associated with beta-amyloid deposits.
Breast MRI and Dense Breasts: A Closer Look at Early Findings from a New Prospective Trial
May 2nd 2024Supplemental breast MRI had a cancer detection rate (CDR) of 20/1000 and a positive predictive value (PPV) of 50 percent, according to preliminary findings from a prospective trial involving women with heterogeneously or very dense breasts.
New Literature Review Finds ChatGPT Effective in Radiology in 84 Percent of Studies
April 29th 2024While noting a variety of pitfalls with the chatbot ranging from hallucinations to improper citations, the review authors found the use of ChatGPT in radiology demonstrated “high performance” in 37 out of 44 studies.